Elevated levels of arginase activity are related to inflammation in patients with COPD exacerbation

BMC Pulm Med. 2021 Aug 21;21(1):271. doi: 10.1186/s12890-021-01629-w.

Abstract

Introduction: Within the pathogenesis of the chronic obstructive pulmonary disease (COPD) there are interactions between different inflammatory mediators that are enhanced during an exacerbation. Arginase is present in bronchial epithelial cells, endothelial, fibroblasts and alveolar macrophages, which make it a probable key enzyme in the regulation of inflammation and remodelling. We aimed to find a potential relationship between arginase activity, inflammatory mediators in COPD patients in stable phase and during exacerbations.

Methods: We performed a prospective, observational study of cases and controls, with 4 study groups (healthy controls, stable COPD, COPD during an exacerbation and COPD 3 months after exacerbation). We measured arginase, inflammation markers (IL-6, IL-8, TNF-∝, IFN-γ and C reactive protein), and mediators of immunity: neutrophils, monocytes, total TCD3 + lymphocytes (CD3ζ), CD4 + T cells, CD8 + T cells, NK cells.

Results: A total of 49 subjects were recruited, average age of 69.73 years (59.18% male). Arginase activity is elevated during an exacerbation of COPD, and this rise is related to an increase in IL-6 production. The levels of IL-6 and IL-8 remained elevated in patients with COPD at 3 months after hospital exacerbation. We did not find a clear relationship between arginase activity, immunity or with the degree of obstruction in COPD patients.

Conclusions: Arginase activity is elevated during an exacerbation of COPD, and it could be related to an increase in the production of IL-6. Levels of IL-6, IL-8, and arginase activity remain elevated in patients with COPD at 3 months after hospital exacerbation. Arginase activity could contribute to the development of COPD.

Keywords: Arginase activity; COPD; COPD exacerbation; Inflammation; Remodelling.

Publication types

  • Observational Study

MeSH terms

  • Aged
  • Aged, 80 and over
  • Arginase / metabolism*
  • Biomarkers / metabolism
  • Case-Control Studies
  • Disease Progression
  • Female
  • Humans
  • Inflammation / metabolism*
  • Inflammation Mediators / metabolism
  • Interleukin-6 / metabolism*
  • Interleukin-8 / metabolism*
  • Linear Models
  • Male
  • Middle Aged
  • Prospective Studies
  • Pulmonary Disease, Chronic Obstructive / diagnosis*
  • Pulmonary Disease, Chronic Obstructive / metabolism
  • Pulmonary Disease, Chronic Obstructive / physiopathology

Substances

  • Biomarkers
  • Inflammation Mediators
  • Interleukin-6
  • Interleukin-8
  • Arginase